Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
Shamsah Kazani, David J. Rowlands, Iván Bottoli, Julie Milojevic, Jose Alcantara, Ieuan Jones, Kenneth Kulmatycki, Surendra Machineni, Lidia Mostovy, Ian A. Nicholls, Jerry A. Nick, Steven M. Rowe, Nicholas J. Simmonds, Raju V. K. Vegesna, Jeroen C. Verheijen, Henry Danahay, Martin Gosling, Phaninatha Sarma Ayalavajjala, Mohammed Salman, Robert M. Strieter
Topics & Concepts
MedicineCystic fibrosisCystic fibrosis transmembrane conductance regulatorPotentiatorIvacaftorAdverse effectPlaceboInternal medicinePharmacokineticsGastroenterologyPharmacodynamicsClinical endpointNauseaRandomized controlled trialPharmacologyPathologyAlternative medicineCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchIon Transport and Channel Regulation